Core Points - BD (Becton, Dickinson and Company) has declared a quarterly dividend of $1.05 per common share, marking a 1.0% increase from the previous quarter, with an annual dividend rate of $4.20 per share for fiscal year 2026 [1][2] - This marks the 54th consecutive fiscal year that BD has raised its dividend, maintaining its status in the S&P 500 Dividend Aristocrats Index, which tracks companies with at least 25 consecutive years of dividend increases [2] - The increase in dividends reflects BD's confidence in its long-term outlook and commitment to returning capital to shareholders, even while executing the Waters RMT transaction [2] Company Overview - BD is one of the largest global medical technology companies, focused on improving medical discovery, diagnostics, and care delivery [2] - The company employs over 70,000 individuals and is dedicated to enhancing the safety and efficiency of healthcare delivery, supporting laboratory scientists, and advancing research capabilities [2] - BD collaborates with organizations worldwide to tackle significant global health challenges, aiming to improve outcomes, lower costs, and expand access to healthcare [2]

Core Insights - BD has achieved full enrollment of the iliac artery patient cohort in its AGILITY study, which evaluates the Revello™ Vascular Covered Stent for treating peripheral arterial disease (PAD) [1][4] - The AGILITY study is a multi-center, prospective study being conducted across 45 investigational sites in the U.S., Europe, Australia, and New Zealand [4] - PAD affects over 21 million Americans and more than 200 million people globally, highlighting the critical need for innovative treatment options [5] Company Overview - BD is a leading global medical technology company focused on improving medical discovery, diagnostics, and care delivery [6] - The company employs over 70,000 individuals and collaborates with organizations worldwide to tackle significant global health challenges [6] Study Details - The AGILITY study aims to assess the safety and effectiveness of the Revello™ Vascular Covered Stent for de novo or restenotic lesions in two patient cohorts: the common and external iliac artery cohort (n=118) and the superficial femoral and proximal popliteal artery cohort (n=223) [7] - The study represents a significant advancement in self-expanding covered stent technology, addressing the need for improved flexibility and deliverability in PAD treatment [3][4]